<SEC-DOCUMENT>0001477932-22-005794.txt : 20220810
<SEC-HEADER>0001477932-22-005794.hdr.sgml : 20220810
<ACCEPTANCE-DATETIME>20220810161841
ACCESSION NUMBER:		0001477932-22-005794
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20220810
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220810
DATE AS OF CHANGE:		20220810

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			VOLITIONRX LTD
		CENTRAL INDEX KEY:			0000093314
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				911949078
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36833
		FILM NUMBER:		221152089

	BUSINESS ADDRESS:	
		STREET 1:		1489 WEST WARM SPRINGS ROAD
		STREET 2:		SUITE 110
		CITY:			HENDERSON
		STATE:			NV
		ZIP:			89014
		BUSINESS PHONE:		1 (646) 650-1351

	MAIL ADDRESS:	
		STREET 1:		1489 WEST WARM SPRINGS ROAD
		STREET 2:		SUITE 110
		CITY:			HENDERSON
		STATE:			NV
		ZIP:			89014

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STANDARD CAPITAL CORP
		DATE OF NAME CHANGE:	19990812
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>vnrx_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:vnrx="http://vnrx.com/20220810"><head><title>vnrx_8k.htm</title><!--Document Created by XBRLMaster--><meta http-equiv="Content-Type" content="text/html" /></head><body style="text-align:justify;font:10pt times new roman"><div style='display:none;text-align:justify;font:10pt times new roman;margin-left:7%;margin-right:7%;' id='XBRLDIV'><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="From2022-08-10to2022-08-10">0000093314</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="From2022-08-10to2022-08-10" format="ixt:booleanfalse">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type='simple' xlink:href='vnrx-20220810.xsd'></link:schemaRef></ix:references><ix:resources><xbrli:context id="From2022-08-10to2022-08-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-10</xbrli:startDate><xbrli:endDate>2022-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="USDPShares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 5px solid;"></td></tr><tr><td style="BORDER-BOTTOM: 2px solid;"></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>UNITED STATES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong>&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Washington, D.C. 20549</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt">FORM <ix:nonNumeric contextRef="From2022-08-10to2022-08-10" name="dei:DocumentType">8-K</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CURRENT REPORT</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PURSUANT TO SECTION 13 OR 15(d) OF</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>THE SECURITIES EXCHANGE ACT OF 1934</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Date of Report (Date of earliest event reported): <strong><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="From2022-08-10to2022-08-10" name="dei:DocumentPeriodEndDate">August 10, 2022</ix:nonNumeric></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong><span style="font-size:18pt"><ix:nonNumeric contextRef="From2022-08-10to2022-08-10" name="dei:EntityRegistrantName">VolitionRx Limited</ix:nonNumeric></span></strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px">(Exact name of registrant as specified in its charter)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:30%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="From2022-08-10to2022-08-10" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></strong></p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:30%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong><ix:nonNumeric contextRef="From2022-08-10to2022-08-10" name="dei:EntityFileNumber">001-36833</ix:nonNumeric></strong></p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:30%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong><ix:nonNumeric contextRef="From2022-08-10to2022-08-10" name="dei:EntityTaxIdentificationNumber">91-1949078</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px">(State or other jurisdiction </p><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px">of Incorporation)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px">(Commission</p><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px">File Number)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px">(IRS Employer</p><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px">Identification Number)&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;&#160; <strong><ix:nonNumeric contextRef="From2022-08-10to2022-08-10" name="dei:EntityAddressAddressLine1">1489 West Warm Springs Road</ix:nonNumeric>, <ix:nonNumeric contextRef="From2022-08-10to2022-08-10" name="dei:EntityAddressAddressLine2">Suite 110</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2022-08-10to2022-08-10" name="dei:EntityAddressCityOrTown">Henderson</ix:nonNumeric>, <ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="From2022-08-10to2022-08-10" name="dei:EntityAddressStateOrProvince">Nevada</ix:nonNumeric> <ix:nonNumeric contextRef="From2022-08-10to2022-08-10" name="dei:EntityAddressPostalZipCode">89014</ix:nonNumeric></strong>&#160;&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Address of principal executive offices and Zip Code) &#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>+1 (<ix:nonNumeric contextRef="From2022-08-10to2022-08-10" name="dei:CityAreaCode">646</ix:nonNumeric>) <ix:nonNumeric contextRef="From2022-08-10to2022-08-10" name="dei:LocalPhoneNumber">650-1351</ix:nonNumeric></strong>&#160;&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Registrant&#8217;s telephone number, including area code ) &#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Not applicable</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Former name or former address, if changed since last report.)</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="From2022-08-10to2022-08-10" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="From2022-08-10to2022-08-10" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="From2022-08-10to2022-08-10" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="From2022-08-10to2022-08-10" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px">Title of Each Class</p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px">Trading Symbol(s)</p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px">Name of Each Exchange on which Registered</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><ix:nonNumeric contextRef="From2022-08-10to2022-08-10" name="dei:Security12bTitle">Common Stock</ix:nonNumeric>,</p><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px">par value $0.001 per share</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><ix:nonNumeric contextRef="From2022-08-10to2022-08-10" name="dei:TradingSymbol">VNRX</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="From2022-08-10to2022-08-10" name="dei:SecurityExchangeName">NYSE American</ix:nonNumeric>, LLC</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">Emerging growth company&#160;&#160; <ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="From2022-08-10to2022-08-10" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;&#9744;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 2px solid;"></td></tr><tr><td style="BORDER-BOTTOM: 5px solid;"></td></tr></tbody></table><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="TEXT-INDENT: 0px;"></td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Form 8-K</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Current Report</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Item 2.02. Results of Operations and Financial Condition.</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The following information, including Exhibit 99.1, is being &#8220;furnished&#8221; in accordance with General Instruction B.2. of Form 8-K and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">On August 10, 2022, VolitionRx Limited (the &#8220;Company&#8221;) issued a press release announcing its financial results and certain business updates for the quarter ended June 30, 2022. The Company also confirmed its conference call to be held on August 11, 2022 at 8:30 a.m. U.S. Eastern Time. Furnished herewith as Exhibit 99.1 and incorporated by reference herein is a copy of the press release.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Item 9.01. Financial Statements and Exhibits.</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">(d) Exhibits.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Exhibit</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Number</strong></p></td><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Description</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="vnrx_ex991.htm">99.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="vnrx_ex991.htm">Press Release of VolitionRx Limited, dated August 10, 2022.</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">104</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document)</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SIGNATURE</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>VOLITIONRX LIMITED</strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="width:50%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Date: August 10, 2022</p></td><td style="width:3%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">By: </p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:35%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ Cameron Reynolds</em></p></td><td style="width:12%;"></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Cameron Reynolds</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Executive Officer &amp; President</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>EXHIBIT INDEX</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Exhibit</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Number</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Description</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="vnrx_ex991.htm">99.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="vnrx_ex991.htm">Press Release of VolitionRx Limited, dated August 10, 2022.</a></p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>vnrx_ex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html><head><title>vnrx_ex991.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>&nbsp; EXHIBIT 99.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>&nbsp;</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>&nbsp;VolitionRx Limited Announces Second Quarter 2022 Financial Results and Business Update</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; text-align:center;"><strong>Conference call to discuss financial and operational results scheduled for</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; text-align:center;"><strong>Thursday, August 11, at 8:30 a.m. U.S. Eastern Time</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Henderson, Nevada, August 10, 2022 /PRNewswire/</strong> -- VolitionRx Limited (NYSE AMERICAN: VNRX) (&#8220;Volition&#8221;) today announced financial results and a business update for the second quarter ended June 30, 2022. Volition management will host a conference call tomorrow, August 11 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#8220;I am delighted with the progress we are making, and in particular could not be prouder of the team&#8217;s achievement in securing a CE Mark for Nu.Q<sup style="vertical-align:super">&#174;</sup> NETs in Europe and in announcing new clinical studies for NETosis, or NETs, in the U.S. with both MD Anderson and with Diagnostic Oncology CRO LLC, or DXOCRO. As the only analytically validated test for NETs currently available, we believe that there is enormous potential for Nu.Q<sup style="vertical-align:super">&#174;</sup> NETs to support clinical decision-making, enabling physicians to act quickly, and improve patient outcomes,&#8221; commented Cameron Reynolds, President and Chief Executive Officer of Volition.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#8220;Following the execution of our global licensing and supply agreement for the Nu.Q<sup style="vertical-align:super">&#174;</sup> Vet Cancer Screening Test with Heska Corporation, the team has been hard at work with the technology transfer program and launch preparation. We also continue to make good progress with other potential licensing and supply partners. Finally, we have recently executed a number of contracts for Nu.Q<sup style="vertical-align:super">&#174;</sup> Discover.&#8221; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>An interview with Cameron Reynolds, President and Group Chief Executive Officer of Volition.</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><u>https://youtu.be/LOoE_kVkrnc</u></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Company Highlights</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong><em><u>Financial</u></em></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Cash and cash equivalents as of June 30, 2022, totaled approximately $16.7 million compared with $20.6 million as of December 31, 2021.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Subsequent to quarter end, Volition received approximately $6.4 million net of underwriter&#8217;s fees and expenses in cash through an underwritten public offering of its common stock that closed on August 2.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Secured a further $1.5 million in non-dilutive funding from Namur Invest Capital Risk in Belgium to fund an early access program for Volition&#8217;s Nu.Q<sup style="vertical-align:super">&#174;</sup> product portfolio at key sites across the EU, UK, and U.S.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Continued to manage expenditures carefully with net cash used in operating activities averaging approximately $2.1 million per month in the quarter.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong><em><u>Personnel/ Operational</u></em></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Appointed Sharon Ballesteros as U.S. Head of Quality and Development Process to spearhead Volition&#8217;s clinical product development program in the U.S. and expanded her team and operations in California.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;width:5%;"> <p style="margin:0px">&nbsp;<strong><em>Nu.Q<sup style="vertical-align:super">&#174;</sup>NETs</em></strong></p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Nu.Q<sup style="vertical-align:super">&#174;</sup> NETs test has been CE marked for the detection and evaluation of NETosis, enabling clinical use in Europe in both ELISA (enzyme-linked immunoassay) and automated ChLIA (ChemiLuminescence ImmunoAssay) formats.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Announced a sponsored research agreement with The University of Texas MD Anderson Cancer Center to evaluate the role of NETS in cancer patients with sepsis.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Appointed DXOCRO to undertake development and clinical validation studies for Volition&#8217;s Nu.Q<sup style="vertical-align:super">&#174;</sup> product portfolio in the United States.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">o</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">DXOCRO will conduct large-scale finding studies across multiple sites in the U.S. using Volition&#8217;s Nu.Q<sup style="vertical-align:super">&#174;</sup> NETs and Nu.Q<sup style="vertical-align:super">&#174;</sup> Cancer tests to determine clinical utility in sepsis and cancer.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">o</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Volition anticipates that subsequent studies will investigatethe chosen intended use claims of the tests, with the objective to gain clearance, authorization, or approval from the United States Food and Drug Administration (the &#8220;FDA&#8221;) and allow the tests to be marketed in the U.S.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">o</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">These multi-site development studies will help demonstrate how Volition&#8217;s Nucleosomics&#8482; technology can directly benefit patients and support our application to the FDA&#8217;s Breakthrough Devices Program and a Pre-submission anticipated in 2023.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">In collaboration with researchers at the University of Namur and QUALIblood in Belgium, published:</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">o </p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">a clinical paper entitled &#8220;<u>NETosis and Nucleosome Biomarkers in Septic Shock and Critical COVID-19 Patients: An Observational Study</u>&#8221;, and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>o </strong></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">a poster presentation entitled &#8220;<u>Evaluation and comparison of NETosis biomarkers in sepsis and COVID-19 patients</u>&#8221; at the International Society on Thrombosis and Haemostasis (ISTH) Congress in July.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Subsequent to quarter end, sponsored a GenomeWeb webinar titled &#8216;The Promise of Neutrophil Extracellular Traps (NETs) as Biomarkers in Inflammatory Disease&#8217;<strong>. </strong>To watch on demand, visit the GenomeWeb <u>website</u>.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Commenced a Market Access Program with European Key Opinion Leaders and early adopters<strong>.</strong></p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong><em><u>Volition Veterinary</u></em></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Following the execution of a global licensing and supply agreement with one of the industry&#8217;s leading companies, Heska Corporation, started the technology transfer and launch preparations with Heska.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">SAGE Healthcare launched the Nu.Q<sup style="vertical-align:super">&#174;</sup> Vet Cancer Test in Singapore.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Advanced negotiations with other potential licensing and supply partners in efforts to make Nu.Q<sup style="vertical-align:super">&#174;</sup> Vet products as accessible as possible worldwide and anticipate further announcements in 2022.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Expanded product claims with the presentation of new clinical data at:</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">o </p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">the European Society of Veterinary Oncology Congress in May. To view click <u>here</u>.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">o </p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">the American College of Veterinary Internal Medicine (ACVIM) in June. To view click <u>here</u>.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Expanded access to a larger clinical research laboratory at Texas A&amp;M University and appointed a veterinary emergency criticalist to commence work in non-cancer indications in addition to developing our clinical research network in Europe.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;width:6%;"> <p style="margin:0px"><strong><em>Nu.Q<sup style="vertical-align:super">&#174;</sup>Capture</em></strong></p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Nu.Q<sup style="vertical-align:super">&#174;</sup> Capture, when used in combination with either sequencing, mass spectrometry and/or Volition&#8217;s Nu.Q<sup style="vertical-align:super">&#174;</sup> assays could potentially aid diagnosis, treatment selection, and both treatment and disease monitoring in addition to aiding biomarker discovery.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">The Nu.Q<sup style="vertical-align:super">&#174;</sup> Capture program now has several strands of technology which:</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">o&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;essentially remove background noise, thereby amplifying the signal,</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">o</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;look to identify the signal in a novel way including through mass spectrometry, or</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">o</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;isolate various chromatin fragments, including nucleosomes and transcription factors.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td colspan="2"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Sponsored a GenomeWeb webinar entitled &#8220;Novel Proteomics Approach to Epigenetic Profiling of Circulating Nucleosomes&#8221; featuring Professor Axel Imhof. To watch on demand, visit the GenomeWeb <u>website</u>.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;width:5%;"> <p style="margin:0px"><strong><em>Nu.Q<sup style="vertical-align:super">&#174;</sup>Discover</em></strong></p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Progressing projects with a range of customers.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Recently signed contracts with three bio-pharmaceutical companies who are accessing our assay portfolio for rapid epigenetic profiling of their drugs in development.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong><em><u>Upcoming Priorities</u></em></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Drive near term revenue in the following key areas:</p></td></tr> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">o</font></p></td> <td style="vertical-align:top;">&nbsp;Licensing of its technology, with a particular but not exclusive focus on Nu.Q<sup style="vertical-align:super">&#174;</sup> Vet.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">o</font></p></td> <td style="vertical-align:top;">Complete Heska Corporation agreement milestones in order to receive further milestone payments.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">o</font></p></td> <td style="vertical-align:top;">Sales of key components of Point of Care test with Heska.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">o</font></p></td> <td style="vertical-align:top;">Sales of kits from non-exclusive agreements for the use of Nu.Q<sup style="vertical-align:super">&#174;</sup> Vet via central reference labs.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">o</font></p></td> <td style="vertical-align:top;">Ongoing and new Nu.Q<sup style="vertical-align:super">&#174;</sup> Discover agreements.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">o</font></p></td> <td style="vertical-align:top;">Sales of its disease monitoring tests (e.g. COVID-19, sepsis).</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Continue to progress the research program for the use of Nu.Q<sup style="vertical-align:super">&#174;</sup> NETs, in monitoring disease progression of COVID-19, sepsis, and potentially other diseases and as a possible companion diagnostic for the treatment of sepsis.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Continue to advance its previously announced large-scale blood, lung, and colorectal cancer trials in Europe, Asia, and the U.S.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Publish several abstracts and peer-reviewed scientific papers with clinical results showing the robustness and utility of its Nu.Q<sup style="vertical-align:super">&#174;</sup> platform.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Advance the development of Nu.Q<sup style="vertical-align:super">&#174;</sup> Capture.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Continue to file patents to expand and extend its intellectual property portfolio.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Event:&nbsp;&nbsp;&nbsp; VolitionRx Limited Second Quarter 2022 Earnings and Business Update Conference Call </strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Thursday, August 11, 2022</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Time:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>08:30 a.m. U.S. Eastern Time</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>U.S. &amp; Canada Dial-in: </strong>1-877-407-9716 (toll free)</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>U.K. Dial-in: </strong>0 800 756 3429 (toll free)</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Toll/International: </strong>1-201-493-6779</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Conference ID: </strong>13732149</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Cameron Reynolds, President and Chief Executive Officer of Volition, will host the call along with Terig Hughes, Chief Financial Officer of Volition, Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, and Scott Powell, Executive Vice President, Investor Relations of Volition. The call will provide an update on important events which have taken place in the second quarter of 2022 and upcoming milestones. </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">A live audio webcast of the conference call will also be available on the investor relations page of Volition&#8217;s corporate website at <u>http://ir.volition.com</u>. In addition, a telephone replay of the call will be available until August 25, 2022. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 13732149.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>About Volition</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Volition is a multi-national epigenetics company that applies its Nucleosomics&#8482; platform through its subsidiaries to develop simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics&#8482;, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid &#8211; an indication that disease is present. Volition is primarily focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Volition&#8217;s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">For more information about Volition, visit Volition&#8217;s website <u>volition.com </u></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The contents found at Volition&#8217;s website address or any other website link or address are not incorporated by reference into this document and should not be considered part of this document. Website addresses and links are included in this document as inactive textual references only.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Media Enquiries:</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Louise Batchelor/Debra Daglish, Volition, <u>mediarelations@volition.com</u> +44 (0)7557 774620</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Safe Harbor Statement</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Statements in this press release may be &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;aims,&#8221; &#8220;targets,&#8221; &#8220;believes,&#8221; &#8220;seeks,&#8221; &#8220;estimates,&#8221; &#8220;optimizing,&#8221; &#8220;potential,&#8221; &#8220;goal,&#8221; &#8220;suggests,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;may,&#8221; &#8220;will&#8221; and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition&#8217;s expectations related to the launch of product sales with Heska, the success of negotiations and the timing, completion and execution of term sheets and/or agreements with third parties regarding the licensing and distribution of Volition&#8217;s products, the timing, completion and delivery of data from clinical studies, the potential uses, benefits and effectiveness of its Nucleosomics&#8482; technology platform, including the Nu.Q<sup style="vertical-align:super">&#174;</sup> NETs test, and the timing and execution of Volition&#8217;s strategy with the FDA. Volition&#8217;s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests, a failure by the marketplace to accept Volition&#8217;s Nu.Q<sup style="vertical-align:super">&#174;</sup> NETs test or other products based on its Nucleosomics&#8482; platform; Volition&#8217;s failure to secure adequate intellectual property protection; Volition&#8217;s failure to obtain necessary regulatory clearances or approvals to distribute and market future products; Volition will face fierce competition and its intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring markets and their rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition&#8217;s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Forward-looking statements are based on current expectations, estimates and projections about Volition&#8217;s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances. </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Nucleosomics&#8482; and Nu.Q<sup style="vertical-align:super">&#174;</sup> and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to &#8220;$&#8221; refer to the legal currency of the United States of America.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>vnrx-20220810.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 08/09/2022-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2022 I-NET Business Solutions, Inc. All Rights Reserved.-->
<schema xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:srt="http://fasb.org/srt/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:vnrx="http://vnrx.com/20220810" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://vnrx.com/20220810">
 <annotation>
  <appinfo>
   <link:roleType roleURI="http://vnrx.com/role/Cover" id="Cover">
    <link:definition>000001 - Document - Cover</link:definition>
    <link:usedOn>link:presentationLink</link:usedOn>
    <link:usedOn>link:calculationLink</link:usedOn>
    <link:usedOn>link:definitionLink</link:usedOn>
   </link:roleType>
   <link:linkbaseRef xlink:type="simple" xlink:href="vnrx-20220810_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
   <link:linkbaseRef xlink:type="simple" xlink:href="vnrx-20220810_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
   <link:linkbaseRef xlink:type="simple" xlink:href="vnrx-20220810_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
   <link:linkbaseRef xlink:type="simple" xlink:href="vnrx-20220810_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
  </appinfo>
 </annotation>
 <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
 <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
 <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
 <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
 <import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
 <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
 <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
 <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
 <import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
 <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
 <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
 <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
 <import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
 <import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
 <import namespace="http://fasb.org/srt-roles/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd" />
 <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
 <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
 <import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
 <import namespace="http://fasb.org/us-roles/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd" />
 <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
 <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
 <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>vnrx-20220810_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 08/09/2022-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2022 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address Address Line 1</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address Address Line 2</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address City Or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address State Or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Security 12b Title</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>5
<FILENAME>vnrx-20220810_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 08/09/2022-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2022 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef  roleURI="http://vnrx.com/role/Cover" xlink:href="vnrx-20220810.xsd#Cover" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/Cover" xlink:title="00000001 - Document - Document and Entity Information" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>vnrx-20220810_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 08/09/2022-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2022 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://vnrx.com/role/Cover" xlink:href="vnrx-20220810.xsd#Cover" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
    <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>vnrx-20220810_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 08/09/2022-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2022 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef  roleURI="http://vnrx.com/role/Cover" xlink:href="vnrx-20220810.xsd#Cover" xlink:type="simple" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCover" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140099763864704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 10, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">VolitionRx Limited<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000093314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 10,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">91-1949078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">1489 West Warm Springs Road<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address Address Line 2</a></td>
<td class="text">Suite 110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Henderson<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">89014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">650-1351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VNRX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>vnrx_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="vnrx-20220810.xsd" xlink:type="simple"/>
    <context id="From2022-08-10to2022-08-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
        </entity>
        <period>
            <startDate>2022-08-10</startDate>
            <endDate>2022-08-10</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-08-10to2022-08-10">0000093314</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-08-10to2022-08-10">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-08-10to2022-08-10">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-08-10to2022-08-10">2022-08-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-08-10to2022-08-10">VolitionRx Limited</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-08-10to2022-08-10">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-08-10to2022-08-10">001-36833</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-08-10to2022-08-10">91-1949078</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-08-10to2022-08-10">1489 West Warm Springs Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-08-10to2022-08-10">Suite 110</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-08-10to2022-08-10">Henderson</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-08-10to2022-08-10">NV</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-08-10to2022-08-10">89014</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-08-10to2022-08-10">646</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-08-10to2022-08-10">650-1351</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-08-10to2022-08-10">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-08-10to2022-08-10">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-08-10to2022-08-10">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-08-10to2022-08-10">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-08-10to2022-08-10">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-08-10to2022-08-10">VNRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-08-10to2022-08-10">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-08-10to2022-08-10">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( %*""E4'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !2@@I5_"XCE>X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2L0P$(=?17)O)TU!EM#M1?&D(+B@> O)[&ZP^4,RTN[;F];=+J(/X#$SOWSS
M#4RGH]0AX7,*$1-9S#>3&WR6.F[9D2A*@*R/Z%2N2\*7YCXDIZ@\TP&BTA_J
M@" XOP6'I(PB!3.PBBN1]9W14B=4%-(9;_2*CY]I6&!& P[HT%.&IFZ ]?/$
M>)J&#JZ &4:87/XNH%F)2_5/[-(!=DY.V:ZI<1SKL5UR98<&WIX>7Y9U*^LS
M*:^Q_,I6TBGBEETFO[9W][L'U@LN1,4W5<-W@LMF(UOQ/KO^\+L*NV#LWOYC
MXXM@W\&ON^B_ %!+ P04    " !2@@I5F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M %*""E7UG_^P000  /@0   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MC9A=<^(V%(;_BL:=Z5436X802($90DB7V23+0)KT8WHA; &:V)(KR8'\^QX9
M8K-;<PP7V+)U7AY+Q^^1Z&^5?C,;SBW9I8DT V]C;7;C^R;:\)292Y5Q"7=6
M2J?,0E.O?9-ISN(B*$W\, @Z?LJ$](;]XMI,#_LJMXF0?*:)R=.4Z8];GJCM
MP*/>YX6Y6&^LN^ /^QE;\P6WOV<S#2V_5(E%RJ412A+-5P-O1&]NPRL74/1X
M$7QKCLZ)>Y2E4F^N,8T'7N"(>,(CZR08'-[YF">)4P*.?P^B7OF;+O#X_%/]
MOGAX>)@E,WRLDE<1V\W ZWHDYBN6)W:NME_XX8$*P$@EIO@FVWW?=N"1*#=6
MI8=@($B%W!_9[C 01P%A]T1 > @("^[]#Q64=\RR85^K+=&N-ZBYD^)1BVB
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M"5?%)7OT@O;:O>"ZBQ$>>3M%Y5ZUL)9+EV5I+@]TII8+%VK*-EKY/$5M>K@
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M<F]P<R]A<' N>&UL4$L! A0#%     @ 4H(*5?PN(Y7N    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 4H(*
M59E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " !2@@I5]9__L$$$  #X$   &
M@($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 4H(*
M59^@&_"Q @  X@P   T              ( !A P  'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " !2@@I5EXJ[',     3 @  "P              @ %@#P
M7W)E;',O+G)E;'-02P$"% ,4    " !2@@I5JL0B%C,!   B @  #P
M        @ %)$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 4H(*520>
MFZ*M    ^ $  !H              ( !J1$  'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ 4H(*5660>9(9 0  SP,  !,
M     ( !CA(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @
&V!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="vnrx_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="vnrx_8k.htm">vnrx_8k.htm</File>
    <File>vnrx-20220810.xsd</File>
    <File>vnrx-20220810_cal.xml</File>
    <File>vnrx-20220810_def.xml</File>
    <File>vnrx-20220810_lab.xml</File>
    <File>vnrx-20220810_pre.xml</File>
    <File>vnrx_ex991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "vnrx_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "calculationLink": {
     "local": [
      "vnrx-20220810_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vnrx-20220810_def.xml"
     ]
    },
    "inline": {
     "local": [
      "vnrx_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "vnrx-20220810_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vnrx-20220810_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "vnrx-20220810.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "vnrx",
   "nsuri": "http://vnrx.com/20220810",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vnrx_8k.htm",
      "contextRef": "From2022-08-10to2022-08-10",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000001 - Document - Cover",
     "role": "http://vnrx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vnrx_8k.htm",
      "contextRef": "From2022-08-10to2022-08-10",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line 1"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line 2"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001477932-22-005794-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001477932-22-005794-xbrl.zip
M4$L#!!0    ( %*""E4MZFE1A@0  (,6   1    =FYR>"TR,#(R,#@Q,"YX
M<V3-6%MOVS84?A^P_\#J91LP29:-!K'AI,BE!0*D&>"T0]X&FJ9M8C*ID90O
M_WZ'U-V67$G.0_-$^GS?N>N0S/33?A.B+96*"7[C!-[ 0903L6!\=>/$RL6*
M,.8@I3%?X%!P>N,<J'(^W?[ZR_2#Z[[=SY[1HR#QAG*-'B3%FB[0CNDU,J*O
M6&DJ73=%_YW8F:"A-_(&U_GO]U@!2W#+ 6&02QY!'Q)+1(QF2QU<^X.Q/QP,
MASGH52SU#DN*L"1KIBG1L<0A6E#%5AR!XR@):(+N?B/H<8WE!D>2;C W0:&[
MK?9R70\B.DBV6FOT._D#&3/HR7WY_ W=QXIQJA1Z%6%L7%%_HB=./'07AFAF
M& K-J*)R2Q>I.D768 1!AKF:[,,;9ZUU-/']W6[G[><R](1<022#D?_VS/B_
M3HJ4=-D(O?)!F@%)+"44ZY"C+5)1XJW$UL^D-E<9!2JZPCARL=8Y:XG5W.I/
MA3X()9O'&NJ<TA0C]49 4-%/]V1=CS22"I3Q+56Z'IS( !Z,W$'@CH*,Q.G*
M=%AC?L:^%"'U4UC.PHRH>DM6=)PB?8BHJLV/E53@2D>R(3<@*4,K3N]&F<N!
M__;U^=6VBI/W"K1#'3P8C\>^E6;0$V2UL8QX#E]7KAFD[ R><?.EDPI^<52D
M%/S13X05**N%7B50EC>NB+F637V;"*LUT?),R4&:5T/JINKEHHKFA99'A(I^
M$/M&;#@#TXK#H&S*-%N#*2NJFJ*L/F(05( \WOS &T!0R4A.$+P%1W#WB =^
MUCI?-S*:QT49O.5RGR/-QB-B8Q&#ZP#.EGRT?!%R\TB7. [!A9C_%^.0+9GY
M9&E(S6%2 93$&LL5U2]X0U6$"3UC#$8PFF+.A;9'A]G"/HH87PJ[05/S>4Q,
MI;Y!AI!9?)\]G:JT,^5!P#'I( ;#)UDF.E(E"[IDG%D[ _,7(+<X%UUD&5/_
M&%K6$,,9^!>_M6LXG100K=_F:$B9*:2)17!(XK CJ?"F@9/^E&6IG+ELNLSH
M$MFI-#&==N,HMHE",T/L;VM[H)EDNEEM_H$ />B8#&*4GYE*-O_'.4D-9RK@
M[#_1<C(U08F(J-0,/LUB-/KO$U.(YUUC @H-?\I@H)>Z!G/4?C]=2-#I74.J
M?ASO'='4+TTCV%1&U13B$5(C?C+ISIW:R97S61"KYPS%[-R,YYJ?W& (%RUO
MKQ:I?UT\*$+KYD'&Z^I!_46DI>V,8(Q^;&^N_H)29U.=HV0;VY@]K%>O]>W,
MESGYKJ<#Q6VEE>T,;A;M+;:XPK0I=IGYDA!-T<>FTX*K2SSIYT4_%YK>4:WR
MG^/MJF<%[#4[G7=P 23:I?LHA/>S%O+P!?;M$A%*6='RN5!R45EJ'GYMW2FS
MWLV'#NG(&!?U1/D1VZHI"D*R[#D*BM=_*ZL9W"S:6VQ\59VU>?*<\6FH5:&C
MI_WR [*O?:OCTE%8?H\V.?(CIMVK'F4O_K'1KNX9WJYZ9!Y>FMT+7WZ>)LG/
MU/3SH'OI:SWH6/V:9WG?ONL5=>F%?T'0]G^.5?M3/]%W^S]02P,$%     @
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M\MB+WY6#]GL70@SIYO1F/^Y^ U!+ P04    " !2@@I5F7LJ%)$"  !$"
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M^'';_,4^![,[8E_LLR%O_P502P,$%     @ 4H(*5:M<6JK"#P  3V@   L
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MS-\\'E_6^EL=WK7BH*_0.(]&X-6!^D."XU:8@E5K\W(GF@L;!H& L,4 J^.
MD:]9IPOP,ZS&_"J7:]%(!?EL2[^)8X]C"#V(PSPOI&Y<.;.RH4@Z_YCI@?81
M(EG'&.(YE"X+1);VC0S\BVU[G"AVV8A+++JI&V@I-'Z'^ @K;]TIN>(3#I*W
MD<G/1F"[9-5^:TH=I:E"Y1%S:@B51(;,P1S))=PG7$GB0$0-$ X64%X; &[1
MKCQ7J-/ >F.Y/CEZEERG[V,@9>OGTWLF%'>HER"B@A!M]Q:E?ZV9PSHRIJV*
MA2*XQ[5_GIV+-:#M.X$ (ZL+SCV$VHR+=\W !86X8!Y] $OZM+G3PK3(M:.?
MG\NA-99PY2QO8&V>R_I+[C& ,6 ":QRV43X^*9??&?WZC.[3:3NI&#E:SE.N
M5VW#KE:JUH>3#=C^%?N>OM\5C_:ULI) D$"-F2!_1H)+ESM('WEV$/+TG.!C
M<O;B("LNVQ3!G3&U&4PF7.)6XI98B$I/8OG[\;C7[D+B,@F]8,;$EOB75^24
MDXNT_VV!S9;GB'^NRX6>:Q_/75<P*9-?5]QG=J%A5TZJY ],Q?Z@8D)ZH8#P
M29)N0)=BXL.7EUK6(5(J-'H1Q.'$QCK\1BG7U@I.KTIC$_[LB'[PX!<:OS(?
M F")-N<KC-U:&)A@I7U*1]P"1(Z[ZXT;=D]=NHC7*Z_W;0!T>/_B81QSGE2M
M%?MO^6)J]N=VEW\_01(3+-0!AX?4(VS*G$CQ>\R[P!@!3.J[!$@@2,,!V1U^
MNYLI583_L<G^BP4 Y?]<,!HO^7'E>''!#UXN9%<!.+W;<>#/P^SC(\NPRT?V
MVY&NQPK$+S^=E.P/IQ+Z>2Q$K(FOT3Z$!-[Q(DQ?":1B%#CA,K)[&=N-=-T$
MBM P],##@]?>D8W?OP3#"D%T7$D1VL["(XU5'Q9@B-43?\0@ID+#2#PJT^ID
M\>"U2WXO!=4<,^<+@:P &2D"L%J8*0R"*1DP+WA :K 1:28GQF]DR#V4+2Y!
MT!3Z(I>H  B=1)ZB/@LBZ<V(A(!+#F=Z9#(@&  7XS@LB$%F*E 1^C2PBK.T
M;1AX,#F.0X?%,<:6M=U62Q?+H^L/J61V9%]</JJ\9N*<2Y.?#@[P6,F  M,!
MW^ES0H,_!%<@#Y@317X2<4MD=_5#I7*Z;$-WE'GDBX Q*Q)4@<@LKB2,A(Q0
M&D&>NQ%(1J5TE$@FBF0/G#@,Y##3N:/(OOV!-"^[I%2VBM!QL5"ZQ=KN,DEQ
M*_<QW:F5UR1X6V'ERESJ;ZI[K,)OVU+?"\#W@%#XHVLPFV [O;<I\H]XDDF"
MZ+*\VQ5JV*6,R+>FL2/+"WS%*L8]WV7^/U+F;P5#*X^'_?2!!YV0=H9#C)G?
MHNP#OH:30?BK=M^NN$9I?W"PF2;$?=]UX5T7?-66,F+B!]2(,C,J^\YF&I'T
MW7CK^$6!/-E*KO=X)C,3]<7Y"A.0\609!#UT5F-KDY'D+\"4VI8Q>^X.^>MD
M*POG1>WY>='=;P#V\3($,KY%G3%I0K8M_[[]S[?$%T%U&:@WFPP";U\>O',%
MD+Q)SK]H89D;,=#?AS&'-]VYDK\-I[9JP_NEI<[$ILWLTD#K3J&!/@Q8T%.!
M\V5I7V%+FW,A%>2>>A$C_VT5+<LF(5[O&.OS(S_65N>+%RS1Y%B1"XW?;[IW
M3\43/R#/%@,W!HK[_&VL5 %2]8_/\]W\L]<BYWH^NF)W[>JJN9.(YE6JG&W?
MQ6B.X75 1U=XH?4+V#BFSW\LE%\Y[D@1" 41P(B,1/"@QA@4AEB2I9*X;,C]
M^'!@7!FSCM)(9Z$L!F_M:KE,]I&8#Z>Z.I9VYOI888C'"K%N'D>6I8%16@$K
M%U[&0"MSH!AE/H[+@"UN)QS4)P5!SENK.93?;M]RQA%OAJ:8?-*(-&,\UB8;
MSS_BLRWQ'#XA<+B%M5)Z^=*^P1ADDWD0@(-L^H$.QR/)="_@:K([@=?D]4%=
M$E_"PS71<WDSG/R!P]0HYX@JM AVSR6, XFGOH.%,NKH.\K8&2^2NU2X,MZ7
M<-?E N5].L\%LJ)<G&_$)0NUQ1V-%UX;6W,%[#E7S18-Y=?SE:ULM#B8&L#[
M<# 6CVS[A@BOW[KK&^V;B]9-/S82A<TBQ,<UW@OIB!D#P>@7@P[!9-4(]1[H
M3.Y]P^'P)<R_YVMYOW>NVGBAIGM'KMK7>$5OQT=UTIW-'4_;U)_?4,FEEJW=
M"'GQMF&"5UNQ"2D5K5(1,):1I_09ET[(1%(SPB,MEW.3V0S A&-#<?N4O62%
M\AI=/.+^FFI+/[<IS?WY=U>R!RY:TS$?<$6JU:)]B%'5@.%K/*Q1 KL6"9_+
M,7/ULWV*T12Z%N'BQTEB/_2)^<!1C[1]X%H4.Y./16 Z,'N^!8^LAD3)\[3/
M&S (S\"5NO-YN/<X!_HZ\%!A()E>L;F'.MDPZ#K$^(].8E^ZCP.2:;*=D]D.
M#N='C!_ AQ(9#?Z$^= SXD"/TP'WXJGTY%01&>-S"*2(A"B>I0F&P@.?'R2.
MOW Q_]J YB'X[N20P=K=VB0LS1*C<5WTSX<0-S@LU'=BV#3$ QUXG($I9"2L
M#\R=7)5Q\DC(R!DG6!1W5_C;K0YT?+)PL>V0+%^"R@E),XV08_D G9 1=*%$
MLQ98Z#$*@D)]'R(L1ZL66);'T$LDM@9%WH'4DP*K!Y&$9 1&1R%>XI-:QG'.
MOR)]9XG$LOJ_D<](.4&T2%"!FVE&X\D 0^\A%RAC^KX3/"6KZ: 0QG(W9IZ+
MM:&4;#N&1D!P3VIEB]#BI$@^%WM%TM+?6_%)'UA=))>IJ@,$P>((4^;,@Z9H
MO5CC,+R)!90#:N'\7$R.;=^;H*V<).=@JD7++F;<B#YBBCL4L00D#)0_BE/!
MN\,9FOYSM@M^TI]IL98*P=6MG7Y*Y"7A]NO*S_PTHCZ!N<$EK-)NR^W+W-X.
MD[<0=EXPZ0@>*GW'YAMN69T.J/-E),"IN(83>(&H_>0XC V'6ZK8YW"G1'\\
MJ: _V<6FU:J-7^TJ--#NUTWZ'=9J-R+O5ONF;N+2P6$MQP:'Q-6^;B&,*.:Y
M\DW+.M3_=K"LME7YOA>N&0!<<DLATFUC,DH=?2?A@BI*]$VS?0;VR\78"2,6
M"#\PXFCK#T[J;\I!ASO%?,G1?7Q,H[ X@<70[0JBZ C 'Q W^2S";LX ;.C4
MWF9-:<%6#SR0\(RE)DLUIU5%A=)[&>JE7VAJ?[HY[W_NMK[3[Z9L''/>9LK5
M<37]KXB+),C^]I+ H1[0S9?DW0B29H=&6$;7^S/QY8<DJ9* $--I%29> P9)
M_Q"S'P2D$_BD ^9 D0]C-#@:J7$@0(;<XFL'_3N,A[?B-< 3XG=&S@KE5XR4
MOU:7W=Y1QUU2^\SSB\FI&>M5XGC\9%!M,21ZXML*V\J1/LYJY%G91(+7ZQPB
MJK-)PY0F:8*! 6D#TS+S \^5=1,:UG/%CG.JOTLJWR;,91YN$^-WML^OU'$V
M!,^9WOKMZ%N_@OQ")^$IP31)?Y-V!ZOQ'F]O)]XNO\?;+XRW6W>_MC^V^P0Y
M??<VOH?W7NE\C4KG>UWSO:[Y79;'=E37?'?)VW')E=WPV$P@XW^4T?A_4$L#
M!!0    ( %*""E4F0EN[X1P  )6T   .    =FYR>%]E>#DY,2YH=&WM/6MW
MVS:6?P6;:3O)64FV;"=.;#=G%5M)-/4CM9VTG2]S(!(2,28)%B!EJ[]^[[T
M2.H1)W$DOZH]9SLQ18(@[ON]%^5)_'HO$CQ\O9?+/!:O1ZF^^H^X>O6JW8(?
M]];LU;W_:38/5% D(LU9H 7/1<@*(],AZQZ\ZYP><9,+W6R^WENSB_55.&8F
M'\?BYR?GW=_/FYW#WKOC'?;?PN1R,-YE;T^.SW=8>SW+62X385@J+IE6"4]W
MV5'G]%WON'G8?0NW;/]87CCMO7M/5YZ\WLO\ZKA0\ZSW[ZY=S:[<?-LYZAW^
ML?.YM7?8>G:URW)QE3=Y+(?ICI;#*-^%A4VN53I\_5/:-]DNZ_[^OO>F=\Y>
MO6JU]];<;WMKV6NVB!U4_R_3B=T$<,Y"SVSG[G?P2<4RERH]O6*',I&(!ITT
M544:P"O.1*#2D/U:< W/LHWUC0WV5J8\#22/V:DP19P;QN&6-X@[PACV,0L!
MES[W70.5YDTC_Q([]%GTYX G,A[O3']4PO50ICOP*4_*PUKX&;6>?^F4]E4Z
M$%K <;" QS'+%0NE"0KXU$%Y$G@"*A.:XTG"W]J=C DB$18QG.E Z67"^LO?
M<1X5VH1\W&"=8@@TR]KM!N,Y>[FSN<YX*VFQCZVS%NL2W:?L'%Z[^ W/W^)<
MZ-X(4^K(7WWZ>Y&&0AN5-MBQ&/&05V>PWK!(O?;A]%A<FDNIQ5KYV:S99'/(
MX^GQ'V==UCGJGO;V._!=GXY/?W_&GO[TCY<;&^LE/=&?[=UG@#!PZH AEJ;"
M&M;H&OUPUO<45! %(<:P/!+,6!K\T]$@?DO(_E6D@FVZW;?*73(X#CX4Q-0O
M)6!KI. K.0MFD#A16JO+&C)\ 1?J> ^[,L+OOL6F*204.9>Q@3]2UL?O*&#[
M?1&KR]82N<$"\,5!L,=X A\1H_R H[Z4>42 R+0::@30I6!<"SCK"Q"7#0*?
M3%D&\)%!$7,-QUW$(4M5CM\/CQ6 ?DP-:)5<\ 1?U-[>!<@'D10C"R]8 D!=
M:!3!G.UWV1'7%X0%QT7KUSU3E)\Z$O@F'CLZ@E^$QMVWM[=0H!1P+L?=<X,K
M=@L-?,EOT2$AO@%/(XAEBNO ND4HX8CH9=US9:1I,/MO^ <\B!LGE*##Z"OX
MS]$!R E+5K0\_7(@^3 %E),!.TD#%:OAF.V?GK##PWU:\.#W$_BSQ3J$1$RE
M,5(&C\?T/?#'"#XI)%TD%X"6;D. 2X4&#,OQ]A$@%^_'HH%P +3" X35 'UA
M20"+-$ C2B>J,"Q3.3R%M/8]YPBH#W]D2N?5D84BD 8HKNFQ0*2P*3S9+!H;
M"?2=TH,\R(%T97 1CQVF)( 0L.,,9 6"715YH  _&XYA /(DB ]P!/L\$<"(
M0,Z.4Q6' (H/@'\RQ,=PJ7U G@'K7@'6Y!*6/!D,9& QS3.$AT%Q;U4,W $/
M#[%"V ^"#X</485FPUCUX<AC^+B4-%3\>(0(H@.0I*4?SR]O .5/(H?#3O'L
MSD 7%BF^Y!P1D+#ZO3 70)%* PJ0A&^4E,PB;@ )10K_T"'RT$L%5%ORC%P$
M46KI(-> $L H+1^!1_$K8@[T&,$E >R#UFZQWX!>8Z.0:><R+8CU I8)-E0J
MK'$A?(="G*^A^=PS0LZ4 J6V2'>+$1.!="(^0B8>6+*RARY0$*5%TK=8A#O0
M@,'FIN1S !(#D%VW/'+?;W3T"D,G!:8'HF\DX1$ZYR^1XCM@\ME7$N0"->.I
M[1>OHSS/S,[:VAC82M'JB[7#$]7]S\6G"YT&>VO%,M7Q&ZZUKY*,IV/V'L0M
MB5RS!#:S9'S9$PD>?FD9V9/&B[=@!M5O6-#E'.6K_ZFO-(CYILDX*@X[Z[LU
M%3X6 [O[G;EV_Z4,\PA^6O_Q"0M$'&<\#&&-GY^LTUNT?T4D$/ [[>?N]:'_
MP2ZP]>/N%*_)5;;[9 $'NH<W3JSA'C+CI*]BXF8O-^'$\3<"XMY:'DYL<8$[
MJQVL]ZI,4 HW$3&; /\A0*L ;0D8$*B1!EG,A$T (DKE'"U/GH'(N)():%7
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MG03$'VOER.:J<N0^X/CR6OMT1P#J'?N6^G_+C._3*W8H$]N16F"#=QQ#1YW
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M4W9*0&%26&V804WAPM>42A<.U;+CDUOX&M@^4#N-%9>U0"'BV82;W(U!!"Z
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M:F69?16.7_\_4$L! A0#%     @ 4H(*52WJ:5&&!   @Q8  !$
M     ( !     '9N<G@M,C R,C X,3 N>'-D4$L! A0#%     @ 4H(*51)R
M;='9 0  BP,  !4              ( !M00  '9N<G@M,C R,C X,3!?8V%L
M+GAM;%!+ 0(4 Q0    ( %*""E69>RH4D0(  $0(   5              "
M <$&  !V;G)X+3(P,C(P.#$P7V1E9BYX;6Q02P$"% ,4    " !2@@I56=QL
MM",&  "C.0  %0              @ &%"0  =FYR>"TR,#(R,#@Q,%]L86(N
M>&UL4$L! A0#%     @ 4H(*51V.90F4!   ="0  !4              ( !
MVP\  '9N<G@M,C R,C X,3!?<')E+GAM;%!+ 0(4 Q0    ( %*""E6K7%JJ
MP@\  $]H   +              "  :(4  !V;G)X7SAK+FAT;5!+ 0(4 Q0
M   ( %*""E4F0EN[X1P  )6T   .              "  8TD  !V;G)X7V5X
=.3DQ+FAT;5!+!08     !P ' , !  ":00     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
